Evidence map›Paper›PMID 38845464›Full record

Trial reportNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2024

Behavioral Activation mHealth Application for Smoking Cessation: A Randomized Controlled Pilot Trial.

Jaimee L Heffner, Edit Serfozo, Kelsey Baker, Melissa Gasser, Noreen Watson, Stacey B Daughters, Elisardo Becoňa, Jennifer B McClure

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jaimee L HeffnerPublic Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0001-9604-5489
Edit SerfozoPublic Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Kelsey BakerPublic Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Melissa GasserDepartment of Psychology, University of Washington, Seattle, WA, USA.
Noreen WatsonPublic Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Stacey B DaughtersDepartment of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Elisardo BecoňaDepartment of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Santiago de Compostela, Spain.
Jennifer B McClureKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.ORCID 0000-0002-2094-9147

Funding

An mHealth mood management tool to improve population-level tobacco cessationR34DA050967 · NIDA · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HEFFNER, JAIMEE · 2020 to 2022
$748k
NIDA NIH HHS R34 DA050967
6 · The paper itself

Abstract

introductionBehavioral activation (BA) is an effective intervention for both depression and substance use disorders. Combining BA with a standard smoking cessation intervention may improve quit rates by addressing depressive symptoms, a key barrier to quitting. This study preliminarily evaluated the acceptability and efficacy of the BA-based Actify! mobile health application (mHealth app) for smoking cessation. AIMS AND

methodsWe conducted a pilot randomized controlled trial (n = 242) comparing Actify! with the National Cancer Institute's (NCI) app for smoking cessation (QuitGuide) on acceptability (user satisfaction, app openings), smoking abstinence, and mechanisms of change (BA and depressive symptoms) at 8 weeks and 6 months postrandomization. Participants were US adults recruited online who smoked daily.

resultsTreatment satisfaction was uniformly higher in the Actify! arm. Number of app openings was similar across arms (M = 34.3 openings over 8 weeks in both arms). Self-reported 30-day point prevalence abstinence (PPA) at 8 weeks was 12.6% for Actify! versus 7.3% for QuitGuide. Differences in 30-day PPA continued through 6 months (18.5% for Actify! vs. 12.2% for QuitGuide). Changes between baseline and 8 weeks in depressive symptoms and BA favored Actify!. Planned subgroup analyses suggested greater benefit of Actify! among participants with pretreatment mild-to-moderate depression symptom severity compared to those with no depression symptoms.

conclusionsActify! showed considerable promise as a novel mHealth treatment, as evidenced by its high usage and higher user satisfaction and quit rates than QuitGuide at both short- and long-term follow-up. The next step is to evaluate Actify! in a fully powered efficacy trial. IMPLICATIONS: Study findings demonstrate the promise of a BA-based mobile health app (Actify!) for smoking cessation as a population-level intervention that can effectively address depressive symptoms as a risk factor for worse smoking treatment outcomes. The Actify! app is the first standalone BA-based app to demonstrate potential for improved acceptability and efficacy relative to a standard care comparison app, with user satisfaction and smoking quit rates descriptively exceeding those of the NCI's QuitGuide app.

Indexed as

Mobile ApplicationsSmoking CessationTelemedicineAdultBehavior TherapyDepressionFemaleHumansMaleMiddle AgedPatient SatisfactionPilot Projects

Identifiers

PMID38845464
PMCPMC11663802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.